Las Vegas, NV – July 14, 2014 – (TechSonian) – Keryx Biopharmaceuticals (NASDAQ:KERX), informed that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,754,257 and No. 8,754,258. The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of ferric citrate prepared from a form of ferric citrate having an intrinsic dissolution rate of at least 1.88/mg/cm2/min, respectively.